Skip Navigation



Hum. Reprod. Advance Access published online on December 19, 2008
Human Reproduction, doi:10.1093/humrep/den459
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
24/4/850    most recent
den459v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fain-Kahn, V.
Right arrow Articles by Morice, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fain-Kahn, V.
Right arrow Articles by Morice, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Feasibility of ovarian cryopreservation in borderline ovarian tumours

V. Fain-Kahn1, C. Poirot2,3, C. Uzan1, M. Prades2, S. Gouy1, C. Genestie2, P. Duvillard1 and P. Morice1,4,5

1 Institut Gustave Roussy, Villejuif 94805, France 2 Groupe Hospitalier Pitié-Salpêtrière, Paris, France 3 UPMC Univ Paris 06, EA 1533, Paris F-75005, France 4 Univ Paris 11, Kremlin-Bicêtre, France

5 Correspondence address. Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France. Tel: +33-1-42-11-51-34; Fax: +33-1-42-11-52-13; E-mail: morice{at}igr.fr

BACKGROUND: Borderline ovarian tumours (BOT) do not exhibit overt stromal invasion and are less aggressive than invasive epithelial ovarian tumours. BOT also arise in younger patients than those who develop epithelial ovarian tumours. Our aim was to evaluate the feasibility of ovarian cryopreservation (OC) in patients treated for BOT.

METHODS: A retrospective study of data concerning young patients (less than 35 years of age) who underwent surgery for a BOT with OC planned during the surgical procedure.

RESULTS: Twenty-three patients, treated between January 2002 and February 2008, were initially selected but six of them were excluded from the present study (four because the tumour was malignant and two because it was benign). Finally, 17 patients were diagnosed as having BOT based on the frozen section analysis. In nine (53%) of these cases, OC was finally performed. In eight cases, OC was not performed; instead, in four cases a simple cystectomy was finally performed (one patient was in fact pregnant at the time of surgery), in one case malignant disease was found and in three (18%) patients OC was not technically feasible because no normal ovarian parenchyma was evident on gross inspection.

CONCLUSION: In patients treated for a BOT, OC was eventually feasible in 53% of patients in whom this procedure was initially planned. In 18%, this procedure was aborted because no macroscopic healthy ovarian tissue could be found.

Key words: borderline tumour/conservative Treatment/infertility/ovarian cryopreservation/recurrence

Submitted on July 22, 2008; resubmitted on November 16, 2008; accepted on November 24, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Uzan, A. Kane, A. Rey, S. Gouy, P. Duvillard, and P. Morice
Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary
Ann. Onc., July 16, 2009; (2009) mdp267v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.